The MMRC Adds Four New Steering Committee Members to Spearhead its Clinical Trial Efforts Nationwide.
The Multiple Myeloma Research Foundation (MMRF) recently announced the election of new Steering Committee members to its clinical trial arm, the Multiple Myeloma Research Consortium (MMRC). Together with current Steering Committee members, they will be responsible for leading efforts to rapidly identify the most innovative and promising myeloma treatments under investigation, and accelerating these agents into the clinic to benefit patients via the MMRC’s innovative and collaborative clinical research network.
The committee is comprised of the following new members:
- Ajai Chari, MD, Icahn School of Medicine at Mt. Sinai, NYC
- Amrita Krishnan, MD, City of Hope, Los Angeles CA
- Nina Shah, MD, University of California, San Francisco CA
- Saad Usmani, MD, Levine Cancer Center, Charlotte NC
These new members will join existing members who will serve out the remainder of their terms in 2020:
- David Avigan, MD, Beth Israel-Deaconess Medical Center, Boston MA
- Irene Ghobrial, MD, Dana Farber Cancer Institute, Boston MA
“We are incredibly fortunate to have these eminent myeloma physicians leading our clinical research program,” said Hearn J. Cho, MD, PhD, MMRF Chief Medical Officer. “They represent the geographic, clinical, and scientific diversity of the Multiple Myeloma Research Consortium. These leaders will keep the MMRC at the forefront of myeloma clinical research in our relentless pursuit of a cure.”
The chief responsibility of the Steering Committee is the review, selection, and prioritization of clinical research projects submitted by the pharma industry and academic institutions for consideration by the MMRC. The key goal of the prioritization process is to identify the most promising myeloma drug candidates and move them through the testing and clinical trials process efficiently so that new treatments might be delivered to patients as quickly as possible.